Gilead Sciences to Acquire Oncology Partner Arcellx in $7.8 Billion Buyout

Gilead Sciences has announced a definitive agreement to acquire its partner Arcellx for $7.8 billion, a move that consolidates its position in the advanced cancer treatment market. The deal has sent Arcellx shares toward record highs as investors react to the significant valuation.

Jack Davies

February 23, 2026789 views

Related Stories

Finance

Stellantis Records First Annual Loss in History Following 20 Billion Euro EV Writedown

1d ago

Finance

Imperial Petroleum Accelerates Fleet Expansion as Valuation Multiples Lag Behind Earnings

1d ago

Finance

Syngenta Prepares $10 Billion Hong Kong IPO for Second Quarter Launch

1d ago

Finance

Uber and Lyft Shares Surge as Trump Administration Scraps Independent Contractor Rule

1d ago

Comments (2)

Sign in to leave a comment.

Natasha Volkov4d ago

* *Refining for Nathan Cole (

00

Reply

Nathan Cole4d ago

This acquisition marks a

00

Reply